A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance
- 5 May 2007
- journal article
- Published by Springer Science and Business Media LLC in Investigational New Drugs
- Vol. 25 (4), 313-326
- https://doi.org/10.1007/s10637-007-9053-8
Abstract
The ability of cancer cells to become simultaneously resistant to different drugs, a trait known as multidrug resistance, remains a major obstacle for successful anticancer therapy. One major mechanism of resistance involves cellular drug efflux by expression of P-glycoprotein (P-gp), a membrane transporter with a wide variety of substrates. Anthracyclines are especially prone to induction of resistance by the P-gp mechanism. P-gp mediated resistance is often confronted by use of P-gp inhibitors, synthesis of novel analogs, or conjugating drugs to macromolecular carriers in order to circumvent the efflux mechanism. In this report, the effect of free and Elastin-like polypeptide (ELP) bound doxorubicin (Dox) on the viability of sensitive (MES-SA and MCF-7) and multidrug resistant (MES-SA/Dx5 and NCI/ADR-RES) human carcinoma cells was studied in vitro. The resistant MES-SA/Dx5 cells demonstrated about 70 times higher resistance to free Dox than the sensitive MES-SA cells, and the NCI/ADR-RES cells were about 30 fold more resistant than the MCF-7 cells. However, the ELP-bound Dox was equally cytotoxic in both sensitive and resistant cell lines. The ELP-bound Dox was shown to accumulate in MES-SA/Dx5 cells, as opposed to free Dox, which was rapidly pumped out by the P-gp transporter. Since ELP is a thermally responsive carrier, the effect of hyperthermia on the cytotoxicity of the ELP-Dox conjugate was investigated. Both cytotoxicity and apoptosis were enhanced by hyperthermia in the Dox resistant cells. The results suggest that ELP-Dox conjugates may provide a means to thermally target solid tumors and to overcome drug resistance in cancer cells.Keywords
This publication has 69 references indexed in Scilit:
- Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude miceJournal of Controlled Release, 2006
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- Mechanisms and strategies to overcome multiple drug resistance in cancerFEBS Letters, 2006
- Genetic Polymorphisms of Drug-Metabolising Enzymes and Drug Transporters in the Chemotherapeutic Treatment of CancerClinical Pharmacokinetics, 2006
- Evaluation of cell penetrating peptides fused to elastin-like polypeptide for drug deliveryJournal of Controlled Release, 2005
- BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTERAnnual Review of Pharmacology and Toxicology, 1999
- A Possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrierEuropean Journal Of Cancer, 1999
- Design and tumor targeting of anthracyclines able to overcome multidrug resistance: A double-advantage approachPharmacology & Therapeutics, 1993
- ABC Transporters: From Microorganisms to ManAnnual Review of Cell Biology, 1992
- Temperature of polypeptide inverse temperature transition depends on mean residue hydrophobicityJournal of the American Chemical Society, 1991